Cargando…
Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
Background: New oral prostacyclin therapies and prostacyclin agonists have become available for the treatment of pulmonary arterial hypertension (PAH). However, methods for transitioning between oral, inhaled, and parenteral formulations are not well-established, except in the form of case reports a...
Autores principales: | Pan, Irene Z., Carey, Jessica R., Jacobs, Joshua A., Dechand, John, Sessions, Joshua J., Sorensen, Teshia, Penn, Brittany A., Mayeux, Jennalyn D., Hatton, Nathan D., Ryan, John J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137736/ https://www.ncbi.nlm.nih.gov/pubmed/32296704 http://dx.doi.org/10.3389/fmed.2020.00081 |
Ejemplares similares
-
Management of Pulmonary Arterial Hypertension
por: Mayeux, Jennalyn D., et al.
Publicado: (2020) -
Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data
por: Ingram, Dominique, et al.
Publicado: (2022) -
Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview
por: Alamri, Ayedh K., et al.
Publicado: (2023) -
Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015) -
Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)